CRISPR,SARS-CoV-2 z-bo 2020-10-22 388

　　On October 15, 2020, Synthego, a genome engineering company, and the Krogan Laboratory of the Quantitative Biological Sciences Institute (QBI) of the University of California, San Francisco, a world-renowned scientific research unit, published an article in Science, providing multiple CRISPR-based engineered cell lines to Accelerate research on potential therapeutic targets of SARS-CoV-2.

　　Researchers used Synthego engineered cells together to target more than 300 genes that the virus interacts with in human cells.

　　"Using Synthego's industry-leading CRISPR-based genome engineering platform is essential to accelerate our research," said Dr. Krogan, a professor at the University of California, San Francisco, director of QBI, and senior researcher at the Gladstone Institute. "The accuracy and reproducibility of CRISPR is the key to helping us study how SARS-CoV-2 affects cellular pathways and ultimately causes disease, enhancing our validation of promising therapeutic targets that may provide extensive prevention of coronaviruses. Protection from infection."

　　Inspired by an article entitled "A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing" published by the University of California, San Francisco, "Nature", Synthego has expanded its expertise and platform technology by editing individual genes and A series of genes to verify the targets identified in the study. This method reveals through infectivity analysis which genes and cellular pathways are necessary for viral infection and/or growth in human cells.

　　The research report’s co-author, Synthego’s head of science, Kevin Holden, said: “Contributing to the key work of an international research team composed of 14 major institutions in 6 countries is a great honor. The recent publication, plus Our upcoming World CRISPR Day (October 20) highlights our growing scientific expertise and leadership in applying the latest genome engineering platform innovations to advance life science research and clinical development."

　　Dr. Krogan will introduce scientific research and collaborative efforts in more detail at Synthego’s upcoming World CRISPR Day seminar. Nobel Prize winner Dr. Jennifer Doudna will also give a keynote speech at this seminar.